Skip to main content
PMC home page
Molecular Cancer logoLink to Molecular Cancer
. 2015 Dec 21;14:213. doi: 10.1186/s12943-015-0487-x

Targeting STAT3/miR-21 axis inhibits epithelial-mesenchymal transition via regulating CDK5 in head and neck squamous cell carcinoma

Shan-Shan Sun 1,#, Xuan Zhou 1,#, Yuan-Yuan Huang 1,#, Ling-Ping Kong 1, Mei Mei 2, Wen-Yu Guo 1, Ming-Hui Zhao 1, Yu Ren 2,✉, Qiang Shen 3,✉, Lun Zhang 1,✉
PMCID: PMC4687320  PMID: 26690371

Abstract

Background

Abnormal activation of STAT3 and miR-21 plays a vital role in progression and invasion of solid tumors. The cyclin-dependent kinase 5 (CDK5) is reported to contribute to cancer metastasis by regulating epithelial-mesenchymal transition (EMT). However, the role of STAT3/miR-21 axis and CDK5 in head and neck squamous cell carcinoma remains unclear.

Methods

We measured the expression of miR-21, CDK5 and EMT markers in 60 HNSCC tumor samples. We used Immunohistochemistry and in situ hybridization assay to examine the role of STAT3/miR-21 axis and CDK5 activation in the invasiveness of HNSCC. The clinical survival relevance was analyzed by Kaplan-Meier analysis and univariate/multivariate COX regression model. Multiple approaches including scratch, transwell chamber assay and other molecular biology techniques were used to validate the anti-invasion effect of targeting miR-21 in Tca8113 and Hep-2 cell lines in vitro. Furthermore, whether miR-21 depletion inhibits HNSCC invasion in vivo was confirmed in Tca8113 xenograft tumor model.

Results

The expression of miR-21 and CDK5 were significantly correlated with lymph node metastasis in HNSCC. Hep-2 and Tca8113 cell lines showed co-overexpression of miR-21 and CDK5. WP1066 or asON-miR-21 treatment depleted miR-21 and CDK5 expression and significantly inhibited migration or invasion in Hep-2 and Tca8113 cells. The expression levels of CDK5/p35, N-cadherin, vimentin, β-catenin were inhibited while E-cadherin level was increased by miR-21 depletion in vitro and in vivo. Conversely, ectopic CDK5 overexpression significantly induced tumor cell motility and EMT. Moreover, ectopic CDK5 overexpression in Hep-2 and Tca8113 cells rescued the observed phenotype after miR-21 silencing or WP1066 treatment.

Conclusions

miR-21 cooperates with CDK5 to promote EMT and invasion in HNSCC. This finding suggests that CDK5 may be an important cofactor for targeting when designing metastasis-blocking therapy by targeting STAT3/miR-21 axis with STAT3 inhibitor or miR-21 antisense oligonucleotide. This is the first demonstration of the novel role of STAT3/miR-21 axis and CDK5/CDK5R1 (p35) in metastasis of HNSCC.

Electronic supplementary material

The online version of this article (doi:10.1186/s12943-015-0487-x) contains supplementary material, which is available to authorized users.

Keywords: CDK5, miR-21, EMT, HNSCC, Lymph node metastasis

Background

Presently there are 600,000 new HNSCC patients worldwide annually [1]. Approximately up to 50 % HNSCC patients achieved 5-year overall survival, suggesting a poor mean survival for this cancer type [2]. Lymph node metastasis or other distant metastasis is one of the most significant factors responsible for the observed poor clinical outcome. Epithelial mesenchymal transition (EMT) is considered as a vital process of metastasis, and thus it may significantly contribute to the progression of HNSCC [3–5].

The oncogenic miR-21 gene is located in chromosome17q23.2 and is evolutionally conserved in vertebrates including humans. MiR-21 is known to play an essential role in regulating biological behaviors in many malignancies [6–8]. MiR-21 is also associated with several biomarkers and therapeutic targets in multiple epithelium cancers such as oral squamous cell carcinoma (OSCC) [9], renal cancer [10], colorectal cancer [11], and etc. MiR-21 has been demonstrated as a key regulator of biological behaviors of cancer cells, including apoptosis [10], proliferation [12], EMT [13], migration and invasion [14]. Accumulating evidence demonstrates that miR-21 participated in EMT via several signal pathways. Luo et al. found that STAT3/miR-21 activation by IL-6 was associated with arsenite-induced EMT of human bronchial epithelial (HBE) cells [15]. Our previous research also suggested that inhibition of STAT3/miR21 axis with WP1066, a small-molecule STAT3 inhibitor, suppressed HNSCC cell growth and sensitized cells to cisplatin [16, 17].

The neuronal kinase CDK5, which functions in migration, was recently reported to be activated in human cancers and implicated in promoting metastasis [18]. CDK5 activation regulates prostate cancer cell motility and metastatic potential [19]. Inhibition of CDK5 activity reduces the tumorigenic and metastatic properties of pancreatic cancer cells [18]. In an orthotropic xenograft model of human pancreatic cancer, inhibition of CDK5 reduces tumor growth and metastasis [18]. CDK5 functions through its regulatory subunit, p35, in multiple caner types. In medullary thyroid carcinoma (MTC), CDK5, p35 and p25 are highly expressed, and CDK5 promotes tumorigenesis and tumor progression via down-regulating its downstream target, Retinoblastoma gene (Rb) [20]. An elevated expression of CDK5 and p35 in lung cancer cells is associated with enhanced lung cancer cell migration and invasion [21].

Although miR-21 and CDK5 respectively regulates HNSCC metastasis, whether miR-21 promotes HNSCC metastasis via regulating CDK5 has not been documented in literature. In the present study, we for the first time demonstrated that miR-21 promotes HNSCC lymph node metastasis and EMT via upregulating CDK5.

Methods

Human tissue samples, IHC staining and ISH

A total of 60 HNSCC tumor samples were included in this study. All the patients received radical resection of tumor and neck lymph node dissection at Tianjin Medical University Cancer Institute & Hospital between January 2008 and December 2012. Ten tissues samples adjacent to tumors were also collected and used as controls. Institutional Human Subject Research Review Committee of Tianjin Medical University approved all procedures. All cases were grouped into positive or negative lymph node metastasis according to the American Joint of Cancer Committee’s Lip and Oral Cancer TNM staging system (2010 version) [22]. All tumor samples and tissues adjacent to tumor were paraffin-embedded and sectioned for routine immunohistochemistry (IHC) staining and in situ hybridization. Hybridization was performed with locked nucleic acid (LNA)-modified antisense miR-21 probe (Boster, China) and IHC for CDK5 (Cell Signaling Technology, USA), N-cadherin (Cell Signaling Technology, USA), Vimentin (BD Bio, CA, USA), β-catenin (Cell Signaling Technology, USA), STAT3/-p (Cell Signal Technology, USA), Ki-67 (Zhongshan, China), cleaved caspase 3 (Cell Signaling Technology, USA) and E-cadherin (Cell Signaling Technology, USA). The In situ hybridization (ISH) and IHC assays were performed as previously described [12].

Cell culture and transfection

The human Hep-2 and Tca8113 cell lines were purchased from the China Center for Type Culture Collection (Wuhan, China) and maintained in modified Eagle’s medium (MEM) and RPMI-1640 (Invitrogen, USA) supplemented with 10 % fetal bovine serum (Gibco, USA). WP1066 (Calbiochem, Germany) was dissolved in DMSO (Solarbo, China) for use and storage. Hep-2 and Tca8113 cells were treated with WP1066 for 48 h at a concentration of 4.5 μM. The asON was transfected by using Lipofectamine 2000 (Invitrogen, USA) at a final concentration of 300 nmol/L and 233 nmol/L, respectively, according to the manufacturer’s instructions. 48 h after transfection, cells were harvested for total RNA or miRNAs isolation, and protein extraction. The CDK5 plasmid (CDK5(BC005115)-GV141) was synthesized by Gene Chem Company, China.

RNA extraction and real-time PCR

Total RNAs were extracted by using the Trizol Reagent (Life technology, USA) in accordance with the manufacturer’s instructions. Both RT and PCR primers were purchased from Gene Pharma (Shanghai, China). Expression of mature miR-21 was measured using miR-21 QPCR kit (Beyotime Biotechnology, China). Relative quantification was conducted using amplification efficiencies derived from cDNA standard curves. Relative gene expressions were obtained. Quantitative analysis of change in expression levels was performed using a real-time PCR machine (7500 ABI; USA). The PCR procedure was performed on the Real-time PCR (Bio-Rad, USA) as described previously [12]. U6 was used as an internal control.

Western blot analysis

WP1066 and asON treated Hep-2 and Tca8113 cells were collected for total protein extraction. Extracted proteins were transferred to PVDF membranes (Millipore, USA) and probed with the primary antibodies against N-cadherin (Cell Signaling Technology, USA), vimentin (BD Bio, CA, USA), β-catenin (Cell Signaling Technology, USA), p-β-catenin (Cell Signaling Technology, USA), E-cadherin (Cell Signaling Technology, USA), CDK5 (Cell Signaling Technology, USA), STAT3/-p (Cell Signal Technology, USA). β-actin (Zhongshan, China) and Histone H2A (Cell Signaling Technology, USA) was used as a loading control in total cell extracts and nuclear extracts.

Immunofluorescence staining

For immunofluorescence staining, Hep-2 and Tca8113 cells were seeded on coverslips and fixed with 4 % paraformaldehyde (PFA, Sigma), treated with 1 % Bovine serum albumin (Equitech-Bio, USA) for 30mins and incubated with the antibodies described above overnight at 4 °C. Alexa Fluor 546Goat Anti-Rabbit IgG (1:400 dilutions, Zhongshan, China) was added for 1 h at 37 °C. DAPI reagent was used to stain the cell nuclei. The cells were visualized using FV-1000 laser scanning confocal microscopes.

Wound healing and transwell assays

Hep-2, Tca8113 and Tca8113P160 cells layers were scratched using a 20 μl sterile pipette tip to form wound gaps. The wound location in the six-well plates was marked. Cells were photographed to record the wound width (0 h). Cells were cultured in serum-free medium. Photographs were taken after 24, 48 and 72-h at the marked wound location to measure the cell migration ability. Cell invasion assays were performed using transwell membranes coated with Matrigel (BD Bio, CA, USA). The lower chamber was filled with 10 % FBS. After 48 h, cells remaining in the upper chamber were removed with cotton swabs, while invading cells were fixed with 3 % paraformaldehyde (Santa Cruz, USA), stained with crystal violet (Solarbo, China). Cells penetrated through the polyethylene terephthalate membrane were counted in ten representative microscopic fields (200 × magnification).

Tca8113 xenograft tumor assay

Tianjin Medical University Animal Care and Use Committee approved all animal experimental protocols. Four nude mice were injected with 107 of Tca8113 cells subcutaneously. Mice were monitored daily and three out of four mice formed tumors. Ten days after xenografting, when the tumor size reached approximately 7 mm in diameter, the tumors were surgically removed, cut into pieces of 1–2 mm3 and re-implanted into the left inguinal region of 20 recipient mice. The mice were randomly divided into four groups (DMSO group, nsON-treated group, WP1066-treated group and asON-treated group) for perspective treatment and observation. At the end of the 23rd day of observation, the mice were sacrificed and the xenograft tumors were removed for formalin fixation and preparation of paraffin-embedded sections.

Statistical analysis

Data were analyzed using software SPSS 17.0. The interrelationship of miR-21, CDK5 and EMT related protein expression with lymph node metastasis status was analyzed using χ2 or Fisher exact test. Spearman’s correlation test was used to analyze the correlation of miR-21, CDK5 and the EMT related proteins with lymph node metastasis status. The results were expressed as mean +/- standard error (SE), which represented the average of at least three experiments and each of them was performed in triplicate. Statistics was determined using the analysis of variance test. A p value less than 0.05 was considered statistically significant.

Statement of human tissue and animals experiments

We confirmed that all the protocols on human tissue examination and animal experiments were approved by the Committee of Medical Ethics at Tianjin Medical University.

Results

Overexpression of miR-21/CDK5 is associated with EMT and lymph node metastasis in HNSCC

In the present study, we determined the expression level of miR-21, CDK5 and EMT-related proteins in 60 HNSCC samples. The clinical staging was determined according to American Joint of Cancer Committee (AJCC) Lip and Oral Cancer TNM staging system (2010 version). As shown in the representative IHC staining and in situ hybridization staining in Fig. 1a and b, expression of miR-21 (red) and CDK5 was elevated in lymph node positive group compared with the negative group (χ2 = 8.906, p =0.003; χ2 = 14.102, p =0.000). MiR-21 and CDK5 were significantly associated with lymph node metastatic status (R = 0.385, p =0.002; R = 0.527,p =0.000). As shown in Fig. 1c and Additional file 1: Figure S2B, the expressions of STAT3 and EMT markers were enhanced in lymph node positive group with significant correlation to lymph node metastatic status in HNSCC samples, for N-cadherin (X2 = 21.365,p =0.000;R = 0.647, p =0.000), vimentin (X2 = 7.358, p =0.007;R = 0.350, p =0.006), E-cadherin (X2 = 21.609, p =0.000;R = -0.645, p =0.000), β-catenin (X2 = 5.742, p =0.017;R = 0.354, p =0.002). All HNSCC samples were analyzed using Kaplan-Meier analysis and a multivariate COX regression model. Analysis showed that the expression of miR-21, CDK5, EMT markers, and lymph node metastasis are closely correlated (Additional file 2: Table S1). Univariate analysis showed significant relationships between the Overall survival (OS) and higher T stage, high expression of CDK5, MiR-21, N-cadherin, Vimentin, low expression of E-cadherin, and lymph node metastasis (p < 0.05). Furthermore, T stage (HR: 1.248-3.392; p < 0.05), MiR-21expression (HR: 1.448-13.607; p < 0.05), and N-cadherin expression (HR: 1.795-38.098; p < 0.05) were identified as the independent factors of the OS, which were analyzed by Multivariate Analysis. Protein level of CDK5 and EMT markers were verified by Western blot in the aforementioned corresponding samples of HNSCC (Additional file 3: Figure S1B).

Fig. 1.

Fig. 1

Open in a new tab

Differential expression of miR-21, CDK5 and EMT-related proteins in lymph node (LN) metastasis and LN-negative HNSCC samples. Protein expression level in lymph node with different status of metastasis is shown for a, MiR-21; b, CDK5; and c, N-cadherin, vimentin, E-cadherin and β-catenin

WP1066 inhibited MiR-21/CDK5 in HNSCC cell lines Hep-2 and Tca8113 in vitro

To investigate the involvement of miR-21 and CDK5 in HNSCC, we examined the expression of miR-21 in different HNSCCs cell lines (Cal-27, Hep-2, Tscca, Tca8113, and Tca8113p160). By qRT-PCR and Western blot analysis, we showed that the expression levels of miR-21 and CDK5 were remarkably higher in Hep-2 and Tca8113 cells than other HNSCCs cell lines, as showed in Fig. 2a and b. We also validated the protein level of STAT3 and pSTAT3 in all the tested cell lines, showing significantly increased pSTAT3 in Hep-2 and Tca8113 cells (Additional file 3: Figure S1A), suggesting a positive correlation of expression of miR-21, CDK5, STAT3 and activated pSTAT3. Therefore, Hep-2 and Tca8113 cells were chosen for further investigation.

Fig. 2.

Fig. 2

Open in a new tab

WP1066 inhibits MiR-21/CDK5 in HNSCC cell lines Hep-2 and Tca8113. a MiR-21 expression in Hep-2 and Tca8113 cells. b CDK5 expression in Hep-2 and Tca8113 cells. c MiR-21 expression level alteration after WP1066 or asON treatment. d CDK5 expression in Hep-2 and Tca8113 cells treated with WP1066. e STAT3 and pSTAT3 expression after WP1066 treatment in Hep-2 and Tca8113 cells

To knockdown miR-21 in Hep-2 and Tca8113 cells, we used WP1066, a specific STAT3 small-molecule inhibitor, and antisense oligonucleotide (asON) to suppress miR-21 activity. MiR-21 relative expression was examined after asON exposure for optimal time and dose, the nsON was used as a control group. The optimal time and dose of WP1066 treatment in Hep-2 and Tca8113 cells were demonstrated in our previous report [16, 17]. As shown in Fig. 2c, miR-21 expression was significantly decreased after WP1066 or asON treatment. Meanwhile, CDK5 expression was suppressed by WP1066 in both Hep-2 and Tca8113 cells (Fig. 2d). Consistent with our previous report, STAT3 and pSTAT3 expression were effectively inhibited by WP1066 when compared with parental and DMSO-treated Hep-2 and Tca8113 cells (Fig. 2e).

Reduction of miR-21 impaired HNSCC migration, invasion and EMT by regulating CDK5/p35 in vitro

We used asON and WP1066 to antagonize miR-21 in Hep-2 and Tca8113 cells. nsON and DMSO were used as controls. After 48 h of treatment, scratch and transwell chamber assay were employed to measure antagonistic effect in in vitro cell migration and invasion. The number of migrating and invading cells in asON and WP1066-treated cultures were reduced relative to the control cells (p < 0.05, Fig. 3a, b), demonstrating that both asON and WP1066 could impair the ability of Hep-2 and Tca8113 cells migration and invasion. Moreover, we examined the MMP-2/MMP-9 expression levels in Hep-2 and Tca8113 cells after WP1066 and asON exposure by Western blot. As shown in Fig. 3c, both MMP-2 and MMP-9 expression was decreased in WP1066 and asON groups. All these results demonstrated that knockdown of miR-21 had a suppressive effect on the migration and invasion ability of HNSCC cells in vitro. We then focused on the effect of knocking-down miR-21 on the EMT-phenotypes of Hep-2 and Tca8113 cells. Western blot showed that in both Hep-2 and Tca8113 cells treated with asON and WP1066, E-cadherin expression level was elevated while the N-cadherin expression was attenuated. In addition, a decreased expression of vimentin was also observed. Importantly, the β-catenin expression in nucleus and cytoplasm were both decreased (Fig. 4a, c), suggesting that antagonism of miR-21 by asON and WP1066 led to EMT reversal in Hep-2 and Tca8113 cells. Immunofluorescence (IF) staining showed a notable reduction of nuclear and cytoplasmic β-catenin in asON and WP1066 groups compared with the control group. We also observed inhibition of N-cadherin and vimentin in asON and WP1066-treated cells, compared with untreated cells. Meanwhile, E-cadherin exhibited opposite expression after treatment (Fig. 4d, Additional file 1: Figure S2A). The alteration of these EMT-related proteins after asON or WP1066 exposure suggests that the EMT in Hep-2 and Tscca8113 cells was suppressed.

Fig. 3.

Fig. 3

Open in a new tab

miR-21 blockade reduces migration and invasion of Hep-2 and Tca8113 cells in vitro. a Wound-healing assay of Hep-2 and Tca8113 cells. b Transwell invasion of Hep-2 and Tca8113 cells. Cells were placed in the upper well of the transwell plate and FBS was added into the lower well of the serum-free media. After 48 h of incubation, the percentage of invaded cells was calculated. (original magnification, x200). c Western blotting of MMP-2/-9 expression in Hep-2 and Tca8113 cells after WP1066 and asON treatment

Fig. 4.

Fig. 4

Open in a new tab

miR-21 blockade reverses EMT by regulating CDK5/p35 in HNSCC cells in vitro. a Expression of EMT-related proteins after asON or WP1066 treatment, analyzed by western blot with normalization to β-actin. b Expressions of CDK5 and p35 after asON and WP1066 treatment, determined by western blot with normalization to β-actin. c β-catenin level in nucleus and cytoplasm, analyzed by western blot with normalization to Histone H2A. d Subcellular location of EMT related markers after asON or WP1066 treatment, observed by immunofluorescence staining (original magnification, x100)

To further elucidate that inhibition of miR-21 reversed EMT through CDK5/p35, CDK5 and p35 expression were detected by Western blot analysis. In Fig. 4b, it showed that CDK5 and p35 were significantly down regulated by asON and WP1066 in Hep-2 and Tca8113 cells, suggesting miR-21 regulates EMT process in a CDK5/p35 dependent manner.

Reduction of miR-21 results in reversal of EMT by regulating CDK5 in HNSCC in vitro and in vivo

In vitro experiments demonstrated that miR-21 reversed EMT process via CDK5/p35. We thus employed a Tca8113 xenograft tumor model to confirm this effect in vivo. The growth rates in WP1066 and asON group were suppressed compared to the control and DMSO groups (Fig. 5a). The impaired tumor growth is a consequence of both decreased proliferation and increased apoptosis as demonstrated by IHC staining of the tumors for Ki-67 and cleaved caspase 3, respectively (Additional file 1: Figure S2C). ISH analysis showed that miR-21 was inhibited by WP1066 and asON (Fig. 5d). IHC staining and western blot demonstrated decreased expression levels of STAT3, pSTAT3, CDK5, N-cadherin, vimentin and β-catenin and increased expression of E-cadherin, as observed in both WP1066- and asON-treated groups in xenograft tumors (Fig. 5b, c, Additional file 1: Figure S2C, Additional file 3: Figure S1D). We further validated that CDK5 is a required component for miR-21 to regulate EMT and invasion. CDK5 was overexpressed in Tca8113p160 cells, and we observed increased expression of EMT markers (Additional file 3: Figure S1E), enhanced migration and invasion in Tca8113p160 cells (Additional file 3: Figure S1 F, G). Moreover, CDK5 overexpression reverted the inhibition of EMT markers expression by asON and WP1066 in Hep-2 and Tca8113 cells (Additional file 3: Figure S1C), suggesting that CDK5 overexpression in HNSCC cells is sufficient to induce tumor cell motility via modulating EMT. These results not only support co-regulation of miR-21 and CDK5, but also establish a causal link connecting miR-21, CDK5 and cancer cell migration, invasion and metastasis.

Fig. 5.

Fig. 5

Open in a new tab

miR-21 blockade leads to reversal of EMT via regulating CDK5 in vivo. a The growth curves of Tca8113 xenograft tumors treated with DMSO, nsON, WP1066, and asON. b HE and IHC staining of CDK5. c IHC staining for alteration of EMT markers (original magnification, x400). d ISH for miR-21 inhibition by WP1066 and asON. e A hypothesis schema demonstrating the relationship among miR-21, STAT3 and CDK5/p35 in EMT of HNSCC

Discussion

In the present study, miR-21 inhibition was shown to reverse the EMT process in HNSCC cells by regulating CDK5/CDK5R1 (p35) with antisense oligonucleotide (asON) or a STAT3 inhibitor WP1066.

The tumor cells undergoing EMT is a characteristic of acquiring migratory and invasive mesenchymal phenotypes. Diverse upstream signaling is implicated in this process. Of particular importance, the Wnt pathway plays an essential role by triggering the translocation of β-catenin to the nucleus, leading to the activation of EMT-related target genes and ultimately promoting EMT [23]. Zhang et al. also reported that activation of Wnt/β-catenin pathway is potentially responsible for the EMT phenotype in SGC7901/ADR cells [24]. In our study, the EMT reversal is supported by notable alteration of nucleus-cytoplasm expression of β-catenin by IF and IHC.

MicroRNAs are defined as a subset of small non-coding RNA, which are less than 22 nucleotides long. In general, they function as negative regulators of target genes at transcriptional and post-transcriptional level. Some of them act as tumor-suppressors while other may act as tumor-promoters. Recently, several miRNAs such as miR-21, have been shown to be involved in EMT [25, 26]. Our previous study has demonstrated that reduction of miR-21 induces glioma cell apoptosis via activating caspases 9 and 3 [10]. Downregulated miR-21 inhibits the growth of human glioblastoma cells through EGFR pathway [12]. However, the mechanisms by which miR-21 regulates EMT is not clear. Han et al. showed that AKT and ERK1/2 pathways are required for miR-21 in mediating EMT and CSC phenotype by targeting PTEN [27]. Similarly, miR-21 inhibits its targets-PTEN and sulfatase-1 (hSulf-1) expression in hepatocellular carcinoma (HCC) cells and finally enhances HCC cell proliferation and movement [28]. Meanwhile, miR-21 directs EMT and enhances the invasive potential of transformed human bronchial epithelial cells by targeting PDCD4 [29]. However, Wang et al. found that ectopic expression of miR-21 could overcome TGF-β growth-inhibitory effect but had no effect on EMT of TGF-β in HaCaT cells [13]. Our results suggest that knockdown of miR-21 could reverse the process of EMT in HNSCC cells via CDK5/p35.

CDK5 is a small serine/threonine cyclin-dependent kinase that belongs to the family of CDKs. In contrast to the cell cycle-related CDKs (e.g. CDKs 1, 2, 4, or 6), CDK5 is not implicated in cell cycle control [30]. Instead, CDK5 is involved in neuronal migration and development during embryogenesis [31]. In neurons, CDK5 has been reported to interact with β-catenin through p35, and regulates the affinity of β-catenin for cadherin by altering the phosphorylation levels of β-catenin [32, 33]. Demelash et al. reported that induction of CDK5 regulated lung cancer cell migration through Achaete-scute complex homologue-1 (ASH1). ASH1 directly modulates the expression ofp35 gene in small cell lung cancer cells [21]. Furthermore, CDK5 can also regulate endothelial cell migration and angiogenesis, suggesting CDK5 may serve as a novel target for anti-angiogenic therapy [34].

It was reported that miR-21 targets a number of important molecules such as PTEN, PDCD4, TIMP3 and TMP1 [35, 36]. CDK5 is also involved in neuregulin-dependent activation of phosphatidylinositol 3-kinase (PI3K) and Akt activity [37], and promotes pancreatic β-cell survival via Fak-Akt signaling pathways [38]. In the present study, we attempted to demonstrate that CDK5 was the functional target of miR-21. Our results suggest that the miR-21/CDK5 axis could partially mediate tumor cell mobility and EMT by targeting STAT3 in HNSCC. Moreover, our previous study revealed that abnormal activation of miR-21/CDK5 axis was associated with breast cancer lymph node metastasis [39].

Although several studies have established that miR-21 could promote EMT in tumor cells by a number of mechanisms, it is for the first time that we demonstrate CDK5 regulation by miR-21 to promote metastasis in HNSCC. Our findings demonstrated the importance of miR-21/CDK5signaling in tumor cell migration and invasion in vitro and in vivo. Our studies suggest the intrinsic connection between CDK5 and miR-21 in modulating EMT in HNSCC. Based on these observations, we believe that targeting miR-21/CDK5 might be a novel and feasible approach for managing metastasis from HNSCC. Innovative strategies targeting miR-21 and CDK5 are currently being pursued in our labs.

Conclusions

MiRNA-21 promotes metastasis of HNSCC via regulating CDK5/CDK5R1 (p35) to enhance EMT. Blocking miR-21 with STAT3 inhibitor WP1066 effectively reversed EMT.

Acknowledgements

This work was supported by grants from the National Science Foundation of China (NSFC 81172573, 81572492) and Committee of Tianjin Science and Technology (13JCYBJC21600).

Abbreviations

EMT

Epithelial-Mesechymal Transition

miR-21

microRNA-21

HNSCC

Head and neck squamous cell carcinoma

CDK5

Cyclin-dependent kinase 5

STAT3

Signal transducers and activators of transcription 3

asON

Antisense oligonucleotide

nsON

nonsense oligonucleotide

DMSO

dimethyl sulfoxide

HBE

Human bronchial epithelial

MTC

Medullary thyroid carcinoma

CSC

Cancer stem cell

Rb

Retinoblastoma

BSA

Bovine serum albumin

IHC

Immunohistochemistry

FISH

Fluorescence in situ hybridization

RT-PCR

Reverse transcription polymerase chain Reation

PVDF

Polyvinylidene Fluoride

PDCD4

Programmed cell death 4

SCLCs

Small cell lung cancers

Additional files

Additional file 1: Figure S2. (3.2MB, jpg)

A, Immunofluorescence showing subcellular location of E-cadherin, N cadherin and beta-catenin after asON or WP1066 treatment. B, IHC staining of STAT3 and vimentin in tumor tissue sections in positively correlation to lymph node metastasis of HNSCC patients. C, IHC showing the altered expression of STAT3/pSTAT3, Ki67 and cleaved caspase 3 after DMSO, nsON, WP1066, and asON treatments in Tca8113 xenograft tumors. (JPG 3251 kb)

Additional file 2: Table S1. (21.1KB, docx)

The K-M analysis and COX regression analysis of 60 HNSCC patients. (DOCX 21 kb)

Additional file 3: Figure S1. (16.5MB, jpg)

A, The expression of STAT3 and pSTAT3 protein in five HNSCC cell lines examined by Western blot. B, Expression of CDK5 and EMT markers in relation to the status of lymph node metastasis of HNSCC tissues. C, Ectopic overexpression of CDK5 in Hep-2 and Tca8113 cells and resulting revert of EMT after miR-21 silencing or WP1066 treatment. D, Expression of CDK5 and EMT markers in mouse xenografts tissues after WP1066 or asON treatment. E, Expressions of EMT markers after CDK5 plasmid transfection in Tca8113P160 cells. F, Induction of tumor cell motility and EMT after ectopic CDK5 overexpression in transwell assay in Tca8113p160 cells. G, Induction of tumor cell motility and EMT after ectopic CDK5 overexpression in scratch assay in Tca8113p160 cells. (JPG 16931 kb)

Footnotes

Shan-Shan Sun, Xuan Zhou and Yuan-Yuan Huang contributed equally to this work.

Competing interests

No conflict of interests was declared in this article.

Authors’ contributions

S-SS and XZ carried out the molecular genetic studies, participated in the sequence alignment and drafted the manuscript. S-SS and Y-YH carried out all the immunoassays. L-PK, W-YG and M-HZ participated in the sequence alignment. MM, YR, and QS participated in the design of the study, performed the statistical analysis and modified the manuscript. YR and LZ conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Contributor Information

Shan-Shan Sun, Email: 416638617sss@163.com.

Xuan Zhou, Email: byron2000zhou@sina.com.

Yuan-Yuan Huang, Email: 2008huang.yuanyuan@163.com.

Ling-Ping Kong, Email: kong.lp@foxmail.com.

Mei Mei, Email: mei_10668@163.com.

Wen-Yu Guo, Email: guowenyu920@163.com.

Ming-Hui Zhao, Email: 1007101880@qq.com.

Yu Ren, Email: renyu0425@yahoo.com.

Qiang Shen, Email: qshen@mdanderson.org.

Lun Zhang, Email: lunzhangchina@163.com.

References

  • 1.Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917. doi: 10.1002/ijc.25516. [DOI] [PubMed] [Google Scholar]
  • 2.Ries LAG, John L. Young J, Keel GE, Eisner MP, Lin YD, Horner M-JD. Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. Natl Cancer Inst SEER Program NIH. 2007:07-6215.
  • 3.Smith A, Teknos TN, Pan Q. Epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncol. 2013;49(4):287–92. doi: 10.1016/j.oraloncology.2012.10.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Chaw SY, Majeed AA, Dalley AJ, Chan A, Stein S, Farah CS. Epithelial to mesenchymal transition (EMT) biomarkers--E-cadherin, beta-catenin, APC and Vimentin--in oral squamous cell carcinogenesis and transformation. Oral Oncol. 2012;48(10):997–1006. doi: 10.1016/j.oraloncology.2012.05.011. [DOI] [PubMed] [Google Scholar]
  • 5.Zhang S, Zhou X, Wang B, Zhang KL, Liu S, Yue K, et al. Loss of VHL expression contributes to epithelial-mesenchymal transition in oral squamous cell carcinoma. Oral Oncol. 2014;50(9):809–17. doi: 10.1016/j.oraloncology.2014.06.007. [DOI] [PubMed] [Google Scholar]
  • 6.Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene. 2007;26(19):2799–803. doi: 10.1038/sj.onc.1210083. [DOI] [PubMed] [Google Scholar]
  • 7.Yan LX, Wu QN, Zhang Y, Li YY, Liao DZ, Hou JH, et al. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res. 2011;13(1):R2. [DOI] [PMC free article] [PubMed]
  • 8.Huang TH, Wu FT, Loeb GB, Hsu R, Heidersbach A, Brincat A, et al. Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. J Biol Chem. 2009;284(27):18515–24. doi: 10.1074/jbc.M109.006676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Danielsson K, Wahlin YB, Gu X, Boldrup L, Nylander K. Altered expression of miR-21, miR-125b, and miR-203 indicates a role for these microRNAs in oral lichen planus. J Oral Pathol Med. 2012;41(1):90–5. doi: 10.1111/j.1600-0714.2011.01084.x. [DOI] [PubMed] [Google Scholar]
  • 10.Zhou XA, Zhang JX, Jia QA, Ren Y, Wang YY, Shi L, et al. Reduction of miR-21 induces glioma cell apoptosis via activating caspase 9 and 3. Oncol Rep. 2010;24(1):195–201. doi: 10.3892/or_00000846. [DOI] [PubMed] [Google Scholar]
  • 11.Fukushima Y, Iinuma H, Tsukamoto M, Matsuda K, Hashiguchi Y. Clinical significance of microRNA-21 as a biomarker in each Dukes’ stage of colorectal cancer. Oncol Rep. 2015;33(2):573–82. doi: 10.3892/or.2014.3614. [DOI] [PubMed] [Google Scholar]
  • 12.Zhou X, Ren Y, Moore L, Mei M, You YP, Xu P, et al. Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest. 2010;90(2):144–55. doi: 10.1038/labinvest.2009.126. [DOI] [PubMed] [Google Scholar]
  • 13.Wang T, Zhang L, Shi C, Sun H, Wang J, Li R, et al. TGF-beta-induced miR-21 negatively regulates the antiproliferative activity but has no effect on EMT of TGF-beta in HaCaT cells. Int J Biochem Cell Biol. 2012;44(2):366–76. doi: 10.1016/j.biocel.2011.11.012. [DOI] [PubMed] [Google Scholar]
  • 14.Han M, Liu M, Wang Y, Mo Z, Bi X, Liu Z, et al. Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells. Mol Cell Biochem. 2012;363(1-2):427–36. doi: 10.1007/s11010-011-1195-5. [DOI] [PubMed] [Google Scholar]
  • 15.Luo F, Xu Y, Ling M, Zhao Y, Xu W, Liang X, et al. Arsenite evokes IL-6 secretion, autocrine regulation of STAT3 signaling, and miR-21 expression, processes involved in the EMT and malignant transformation of human bronchial epithelial cells. Toxicol Appl Pharmacol. 2013;273(1):27–34. doi: 10.1016/j.taap.2013.08.025. [DOI] [PubMed] [Google Scholar]
  • 16.Zhou X, Ren Y, Liu A, Han L, Zhang K, Li S, et al. STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo. Oncol Rep. 2014;31(5):2173–80. doi: 10.3892/or.2014.3114. [DOI] [PubMed] [Google Scholar]
  • 17.Zhou X, Ren Y, Liu A, Jin R, Jiang Q, Huang Y, et al. WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR-21 axis. Sci Rep. 2014;4:7461. doi: 10.1038/srep07461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Feldmann G, Mishra A, Hong SM, Bisht S, Strock CJ, Ball DW, et al. Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res. 2010;70(11):4460–9. doi: 10.1158/0008-5472.CAN-09-1107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Strock CJ, Park JI, Nakakura EK, Bova GS, Isaacs JT, Ball DW, et al. Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res. 2006;66(15):7509–15. doi: 10.1158/0008-5472.CAN-05-3048. [DOI] [PubMed] [Google Scholar]
  • 20.Pozo K, Castro-Rivera E, Tan C, Plattner F, Schwach G, Siegl V, et al. The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell. 2013;24(4):499–511. doi: 10.1016/j.ccr.2013.08.027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Demelash A, Rudrabhatla P, Pant HC, Wang X, Amin ND, McWhite CD, et al. Achaete-scute homologue-1 (ASH1) stimulates migration of lung cancer cells through Cdk5/p35 pathway. Mol Biol Cell. 2012;23(15):2856–66. doi: 10.1091/mbc.E10-12-1010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4. doi: 10.1245/s10434-010-0985-4. [DOI] [PubMed] [Google Scholar]
  • 23.Sanchez-Tillo E, de Barrios O, Siles L, Cuatrecasas M, Castells A, Postigo A. beta-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci U S A. 2011;108(48):19204–9. doi: 10.1073/pnas.1108977108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Zhang B, Yang Y, Shi XT, Liao WY, Chen M, Cheng ASL, et al. Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt/GSK-beta/beta-catenin signaling and epithelial-mesenchymal transition. Cancer Lett. 2015;356(2):704–12. doi: 10.1016/j.canlet.2014.10.016. [DOI] [PubMed] [Google Scholar]
  • 25.Zeng T, Peng LF, Chao CH, Fu B, Wang GX, Wang YB, et al. miR-451 inhibits invasion and proliferation of bladder cancer by regulating EMT. Int J Clin Exp Patho. 2014;7(11):7653–62. [PMC free article] [PubMed] [Google Scholar]
  • 26.Lim BJ, Jung SS, Choi SY, Lee CS. Expression of metastasis-associated molecules in non-small cell lung cancer and their prognostic significance. Mol Med Rep. 2010;3(1):43–9. doi: 10.3892/mmr_00000216. [DOI] [PubMed] [Google Scholar]
  • 27.Han ML, Liu MR, Wang YM, Chen X, Xu JL, Sun Y, et al. Antagonism of miR-21 Reverses Epithelial-Mesenchymal Transition and Cancer Stem Cell Phenotype through AKT/ERK1/2 Inactivation by Targeting PTEN. PloS one. 2012;7(6):e39520. [DOI] [PMC free article] [PubMed]
  • 28.Bao LL, Yan Y, Xu C, Ji WD, Shen SW, Xu GY, et al. MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. Cancer Lett. 2013;337(2):226–36. doi: 10.1016/j.canlet.2013.05.007. [DOI] [PubMed] [Google Scholar]
  • 29.Luo F, Ji J, Liu Y, Xu Y, Zheng G, Jing JF, et al. MicroRNA-21, up-regulated by arsenite, directs the epithelial-mesenchymal transition and enhances the invasive potential of transformed human bronchial epithelial cells by targeting PDCD4. Toxicol Lett. 2015;232(1):301–9. doi: 10.1016/j.toxlet.2014.11.001. [DOI] [PubMed] [Google Scholar]
  • 30.Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Proliferat. 2003;36(3):131–49. doi: 10.1046/j.1365-2184.2003.00266.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Utreras E, Henriquez D, Contreras-Vallejos E, Olmos C, Di Genova A, Maass A, et al. Cdk5 regulates Rap1 activity. Neurochem Int. 2013;62(6):848–53. doi: 10.1016/j.neuint.2013.02.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Schuman EM, Murase S. Cadherins and synaptic plasticity: activity-dependent cyclin-dependent kinase 5 regulation of synaptic beta-catenin-cadherin interactions. Philos T Roy Soc B. 2003;358(1432):749–56. doi: 10.1098/rstb.2002.1256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Kwon YT, Gupta A, Zhou Y, Nikolic M, Tsai LH. Regulation of N-cadherin-mediated adhesion by the p35-Cdk5 kinase. Curr Biol. 2000;10(7):363–72. doi: 10.1016/S0960-9822(00)00411-5. [DOI] [PubMed] [Google Scholar]
  • 34.Liebl J, Weitensteiner SB, Vereb G, Takacs L, Furst R, Vollmar AM, et al. Cyclin-dependent kinase 5 regulates endothelial cell migration and angiogenesis. J Biol Chem. 2010;285(46):35932–43. doi: 10.1074/jbc.M110.126177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol. 2008;28(17):5369–80. doi: 10.1128/MCB.00479-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Shi Z, Zhang J, Qian X, Han L, Zhang K, Chen L, et al. AC1MMYR2, an inhibitor of dicer-mediated biogenesis of Oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression. Cancer Res. 2013;73(17):5519–31. doi: 10.1158/0008-5472.CAN-13-0280. [DOI] [PubMed] [Google Scholar]
  • 37.Li BS, Ma W, Jaffe H, Zheng Y, Takahashi S, Zhang L, et al. Cyclin-dependent kinase-5 is involved in neuregulin-dependent activation of phosphatidylinositol 3-kinase and Akt activity mediating neuronal survival. J Biol Chem. 2003;278(37):35702–9. doi: 10.1074/jbc.M302004200. [DOI] [PubMed] [Google Scholar]
  • 38.Daval M, Gurlo T, Costes S, Huang CJ, Butler PC. Cyclin-dependent kinase 5 promotes pancreatic beta-cell survival via Fak-Akt signaling pathways. Diabetes. 2011;60(4):1186–97. doi: 10.2337/db10-1048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Ren Y, Zhou X, Yang JJ, Liu X, Zhao XH, Wang QX, et al. AC1MMYR2 impairs high dose paclitaxel-induced tumor metastasis by targeting miR-21/CDK5 axis. Cancer Lett. 2015;362(2):174–82. doi: 10.1016/j.canlet.2015.03.038. [DOI] [PubMed] [Google Scholar]

Articles from Molecular Cancer are provided here courtesy of BMC

RESOURCES